Key facts
- This page summarizes Joe E. Kiani's Form 4 filing for IRADIMED CORP (IRMD).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 Sep 2026, 16:45.
Joe E. Kiani - 23 Sep 2026 Form 4 Insider Report for IRADIMED CORP (IRMD)
- Reporting relationship
- Director
- Issuer ticker
- IRMD
- Reported as of
- 23 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Sep 2026, 16:45:02 UTC
- Prior SEC filing
- 25 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joe E. Kiani
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Joe E. Kiani filed Form 4 for IRADIMED CORP (IRMD) on 25 Sep 2026.
Change
- Previous filing in this sequence was filed on 25 Sep 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001228621
Primary reporting owner
KIANI JOE E
- Relationship
- Director
- Address
- C/O IRADIMED CORPORATION, 12705 INGENUITY DRIVE, ORLANDO
- Signature
- /s/ Joe E. Kiani
- Signature date
- 25 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IRMD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +698
- Change %
- Price
- Shares after
- 698
- Date
- 23 Sep 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IRMD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -698
- Change %
- -33%
- Price
- $0.000000*
- Shares after
- 1,397
- Date
- 23 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 698
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.
Footnote F2
The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on September 23, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.